Celgene Share Price

CELG

Delayed Nasdaq Other stock markets 21:00:00 20/11/2019 GMT			5-day change	1st Jan Change
108.24 ^USD	+0.10%		-1.97%	+68.89%

14/06/23	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
08/09/21	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI

News in other languages: Celgene

07/04/21	DGAP-WpÜG: Angebot zum Erwerb / Zielgesellschaft: ; Bieter: qqqqq
25/03/21	Leonteq wird neue Emittentin an der BX Swiss AG im Segment «deriBX»
02/02/21	BX Swiss AG startet Handel in neuem Bondsegment
07/07/20	Die BX Swiss AG erhält von der FINMA die Zulassung zur Führung des Schweizer Beraterregisters
03/07/20	Möbel Markt mömax wird neuer Ankermieter im Rüti Center in Pratteln

More news

Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).

Employees

Sector

More about the company

Market Cap	77.04B 67.57B 62.58B 57.58B 109B 7,373B 111B 746B 293B 3,621B 289B 283B 12,505B	P/E 2017	28.7x	P/E 2018	11.6x
Enterprise Value	91.26B 80.04B 74.13B 68.21B 129B 8,734B 132B 884B 347B 4,289B 343B 335B 14,813B	EV / Sales 2017	6.61x	EV / Sales 2018	3.86x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

14/06/23	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
08/09/21	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI
22/06/21	Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity	CI
22/02/21	Celgene Corporation Issues Notice of Redemption of Notes	CI
04/02/21	Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion	CI
04/01/21	Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors	CI
22/12/20	Amgen : Signs Licensing Agreement With Medicines Development for Global Health	MT
05/11/20	Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook	MT
22/09/20	Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors	CI
21/09/20	Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors	CI
25/03/20	Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene	CI
10/03/20	Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors	CI
04/03/20	Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis	CI

28/02/23	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
25/08/22	Not What The Doctor Ordered: Authorisation Application Withdrawn For Pharma Patent Settlement In Australia	AQ
29/07/22	Authorisation request for proposed settlement between pharmaceutical companies withdrawn	AQ
24/02/22	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
04/08/21	Celgene : Sun Pharma And Celegene Settle Patent Dispute Over Lenalidomide (Revlimid®)	AQ

	2017	2018
Net sales	13B 11.4B 10.56B 9.72B 18.38B 1,245B 18.74B 126B 49.38B 611B 48.83B 47.76B 2,111B	15.28B 13.4B 12.41B 11.42B 21.6B 1,463B 22.02B 148B 58.03B 718B 57.38B 56.13B 2,480B
Net income	2.94B 2.58B 2.39B 2.2B 4.16B 281B 4.24B 28.47B 11.16B 138B 11.04B 10.8B 477B	4.05B 3.55B 3.29B 3.02B 5.72B 387B 5.83B 39.17B 15.36B 190B 15.19B 14.86B 657B
Net Debt	3.79B 3.33B 3.08B 2.84B 5.36B 363B 5.47B 36.72B 14.4B 178B 14.24B 13.93B 616B	14.22B 12.47B 11.55B 10.63B 20.11B 1,361B 20.5B 138B 54B 668B 53.4B 52.23B 2,308B

Celgene Share Price

Stocks

CELG

Valuation: Celgene

Latest news : Celgene

Press Releases: Celgene

News in other languages: Celgene

Quotes and Performance

Financials

Company Profile